Olanzapine IP & Risperidone IP [11.23]-CMP142 — Monograph & Safety

1. Clinical & Scientific Overview

Olanzapine IP & Risperidone IP (TIP-MED-000412, Reference Code [11.23]-CMP142) is classified under CNS & Psychiatric Medicines (Ch 11) as a Second-Generation (Atypical) Dibenzothiazepine Antipsychotic & Mood Stabiliser. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Atypical antipsychotic comparators: Olanzapine (Oleanz 5–20 mg; high metabolic/weight-gain risk) and Risperidone (Sizodon 1–4 mg; high hyperprolactinaemia risk).

Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Atypical antipsychotic comparators: Olanzapine (Oleanz 5–20 mg; high metabolic/weight-gain risk) and Risperidone (Sizodon 1–4 mg; high hyperprolactinaemia risk).

Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)

Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

4. Therapeutic Indications & Evidence-Supported Uses

Schizophrenia
bipolar I/II acute mania, bipolar depression, and maintenance
adjunctive treatment in major depressive disorder

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Atypical antipsychotic comparators: Olanzapine (Oleanz 5–20 mg; high metabolic/weight-gain risk) and Risperidone (Sizodon 1–4 mg; high hyperprolactinaemia risk).

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [11.23].

Metabolism & Biotransformation:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

Elimination & Renal Adjustment:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

Hepatic Impairment Considerations:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:

Contraindications: Concomitant strong CYP3A4 inhibitors (Ketoconazole, Itraconazole, Ritonavir). • Precautions: Least extrapyramidal risk among antipsychotics (preferred in Parkinson's psychosis alongside clozapine), but causes orthostatic hypotension, metabolic syndrome (hyperglycaemia/dyslipidaemia), and cataracts.

Key Clinical Precautions: Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:

Somnolence, postural dizziness, dry mouth, weight gain, constipation, mild T4 reduction.
Hyperglycaemia/new-onset diabetes, dyslipidaemia, QT prolongation, neuroleptic malignant syndrome.

Serious / Dose-Limiting Adverse Effects:

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

Phenytoin / Carbamazepine -> increase quetiapine clearance 5-fold (reduces efficacy); Ketoconazole / Clarithromycin -> toxic accumulation; Antihypertensives -> orthostatic syncope

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.23].

Pharmacist Patient Counselling Points:

Patient Counselling Checklist: Take bedtime doses before sleep; rise slowly from sitting/lying to avoid dizziness; swallow SR/XR tablets whole on an empty stomach or light meal.
Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

13. Related Reference Monographs, Educational Guides & Visual Concept

💊 Related Pharmacological / Category Profiles

[11.5] Alprazolam — Short-to-Intermediate Acting Triazolobenzodiazepine (GABA-A Recep
[11.6] Lorazepam (Oral Tablets & Parenteral IV/IM Status Epilepticus) — Intermediate-Acting 3-Hydroxy Benzodiazepine (Direct Phase-II Glu
[11.7] Amitriptyline Hydrochloride — Tertiary-Amine Tricyclic Antidepressant (TCA; Serotonin & Norepin
[11.17] Zolpidem Tartrate (Non-BZD Z-Drug Hypnotic) — Non-Benzodiazepine Imidazopyridine Hypnotic ('Z-Drug'; Selective

📚 Related Knowledge Hub Educational Articles

Receptor Pharmacodynamics & Mechanism of Action Illustration

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback